Ivonescimab BLA receives Complete Response Letter from FDA
Ivonescimab BLA receives Complete Response Letter from FDA
Conclusion: The FDA issued a Complete Response Letter (CRL) on ivonescimab's BLA for previously treated, EGFR-mutated NSCLC. The agency said the HARMONi trial's progression-free survival (PFS) benefit cannot support approval without a statistically significant overall survival (OS) benefit. The FDA also raised regional-data, exploratory-analysis and benefit-risk concerns, and asked for a new adequate, well-controlled global trial if Summit wants to pursue this indication. Near-term US approval in this setting looks unlikely. The realistic paths are a resubmission (which Summit is reportedly considering), a new global trial, or survival-positive data from HARMONi-3.
Data as of 2026-11-18. Sources run through 2026-11-17.
Premise check: the "0.012" miss. I could not verify a 0.012 figure in any source. The OS result is a hazard ratio of (95% CI 0.62–1.01). One secondary summary gives a primary-analysis p-value of (April 2025 cut), which is above the conventional 0.05 threshold. I did not find that p-value in the primary press release. If you meant a different metric, please send the source.
What the FDA decided
- Summit announced the CRL on . Fierce Biotech reports the letter is dated November 13. One secondary source describes the goal date as November 14.
- The letter says the BLA "cannot be approved in its present form" because "substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement." It adds that a PFS benefit without statistically significant OS "does not support a positive benefit-risk profile." (Summit press release.)
- Per Morningstar/Dow Jones, the letter cites three further reasons:
- PFS data mostly from China-enrolled patients do not reflect the US population.
- The post-hoc PFS and OS analyses are exploratory, not confirmatory.
- The modest benefit does not outweigh the drug's risks.
- Fierce reports that of PFS events occurred in China-enrolled patients. It also quotes the FDA calling the post-hoc OS analyses "exploratory only" and noting differential data-cutoff dates across regions.
What the trial data showed (HARMONi, n=438, global Phase III vs placebo plus chemotherapy)
- PFS was met: , HR .
- Primary OS was not significant: , HR 0.79. One source gives 18.6 vs 14 months (BioSpace), so the OS medians are inconsistent across sources.
- Western-patient OS hazard ratio moved from 0.98 (April 2025) to 0.84 (September 2025) to 0.76 (June 2026). The 0.76 figure matches the full population and Asian patients. Summit labels these later cuts post hoc and reports nominal p-values. Healio gives the same HR sequence.
- Safety: TRAE discontinuations were on ivonescimab vs 5.0% on placebo. TRAE deaths were 1.8% vs 2.3% (chemotherapy alone). The FDA reportedly recognised the safety profile.
Why the FDA held the line. The FDA's OS requirement was stated during development, according to Akeso's CEO quoted by Fierce. A relevant precedent is amivantamab (MARIPOSA-2). It was approved in September 2024 for the same post-TKI EGFR population on a PFS HR of 0.48, with no significant OS difference at the second interim analysis (HR 0.73). Apoapen notes the FDA did not apply the OS bar there. The regional-enrollment issue is specific to ivonescimab. HARMONi was designed as a continuation of China's HARMONi-A trial, and the global arm started enrolling in the US and Europe about 1.5 years later, per Fierce.
Remaining options and uncertainties
- Resubmission or FDA meeting. Summit's regulatory chief said plans "probably involve meeting with the FDA" but gave no details (). Citi, after speaking with management, says Summit is contemplating a resubmission. Fierce says the FDA asked for a new global trial. A resubmission on existing data would require the FDA to reverse its position on OS and regional data, which the letter makes hard.
- New global trial. This is the FDA's stated route for this indication, but the sources give no timeline or design.
- HARMONi-3 (first-line NSCLC). Its squamous-cohort PFS final analysis is expected in Q4 2026 per Apoapen, and Leerink calls it the critical catalyst. HARMONi-7 (monotherapy, high PD-L1) is also in Phase III. A survival-positive HARMONi-3 would be the strongest path to the US label, but the sources do not say whether it will show OS significance.
- Other indications and partners. Summit lists CRC, urothelial and RCC programs, and partner combinations with AstraZeneca/Daiichi Sankyo and Arcus. Akeso holds China rights, where ivonescimab is already approved in NSCLC (Morningstar).
- Counter-view. Summit's CEO calls this an isolated case in a "relatively small indication." TD Cowen argued the eventual survival signal should suffice (BioPharma Dive). Leerink pointed to the FDA's explicit OS statement. The sell-side split is visible but does not change the FDA's written position.
My read: This is a regulatory-standard loss, not a safety rejection. Summit's leverage now depends on HARMONi-3 and on whether the FDA accepts a new global design. The biggest unknowns are the HARMONi-3 squamous OS/PFS outcome, the timing and design of any new trial, and whether Summit's post-hoc western OS data are enough for the FDA to reconsider. None of these is resolved by the data available as of 2026-11-18.
Sources
- Summit Therapeutics press release, Nov 15, 2026 (primary; read in full)
- Fierce Biotech, "FDA's complete response letter... cites China-heavy data," Nov 17, 2026 (read in full)
- Morningstar/Dow Jones, "Summit Therapeutics' stock tumbles again as FDA recommends new trial," Nov 17, 2026 (read in full)
- Apoapen, "FDA Rejects Ivonescimab in EGFR-Mutant Lung Cancer," Nov 15, 2026 (search summary)
- Healio, "FDA rejects ivonescimab...," Nov 16, 2026 (search summary)
- BioSpace, "FDA's Summit rejection puts PD-1xVEGF class on notice," Nov 16, 2026 (search summary)
- BioPharma Dive, "Summit shares fall as FDA rejects...," Nov 16, 2026 (search summary)
- Fierce Pharma, "FDA rejects Summit Therapeutics' PD-1/VEGF ivonescimab in NSCLC," Nov 15, 2026 (search summary)
- Pink Sheet (Citeline), "Ivonescimab CRL Indicative of FDA View on OS Significance," Nov 16, 2026 (search summary)